Switch theme
Sign up to access all valuation multiples
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
2004
7
LTM Revenue $0.5M
Last FY EBITDA -$5.7M
$13.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lexaria Bioscience has a last 12-month revenue (LTM) of $0.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Lexaria Bioscience achieved revenue of $0.5M and an EBITDA of -$5.7M.
Lexaria Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lexaria Bioscience valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.5M | XXX | $0.5M | XXX | XXX | XXX |
| Gross Profit | $0.5M | XXX | $0.5M | XXX | XXX | XXX |
| Gross Margin | 99% | XXX | 99% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$5.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1223% | XXX | XXX | XXX |
| EBIT | -$9.6M | XXX | -$5.8M | XXX | XXX | XXX |
| EBIT Margin | -2114% | XXX | -1239% | XXX | XXX | XXX |
| Net Profit | -$9.6M | XXX | -$5.8M | XXX | XXX | XXX |
| Net Margin | -2114% | XXX | -1248% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lexaria Bioscience's stock price is $1.
Lexaria Bioscience has current market cap of $19.8M, and EV of $13.3M.
See Lexaria Bioscience trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13.3M | $19.8M | XXX | XXX | XXX | XXX | $-0.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lexaria Bioscience has market cap of $19.8M and EV of $13.3M.
Lexaria Bioscience's trades at 29.1x EV/Revenue multiple, and -2.2x EV/EBITDA.
Equity research analysts estimate Lexaria Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lexaria Bioscience has a P/E ratio of -2.1x.
See valuation multiples for Lexaria Bioscience and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.8M | XXX | $19.8M | XXX | XXX | XXX |
| EV (current) | $13.3M | XXX | $13.3M | XXX | XXX | XXX |
| EV/Revenue | 29.4x | XXX | 29.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -2.2x | XXX | XXX | XXX |
| EV/EBIT | -1.4x | XXX | -1.8x | XXX | XXX | XXX |
| EV/Gross Profit | 29.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.1x | XXX | -2.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLexaria Bioscience's last 12 month revenue growth is 117%
Lexaria Bioscience's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.9M for the same period.
Lexaria Bioscience's rule of 40 is -1896% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lexaria Bioscience's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lexaria Bioscience and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 117% | XXX | 65% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1896% | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 508% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1338% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanoform | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lexaria Bioscience acquired XXX companies to date.
Last acquisition by Lexaria Bioscience was XXXXXXXX, XXXXX XXXXX XXXXXX . Lexaria Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lexaria Bioscience founded? | Lexaria Bioscience was founded in 2004. |
| Where is Lexaria Bioscience headquartered? | Lexaria Bioscience is headquartered in United States of America. |
| How many employees does Lexaria Bioscience have? | As of today, Lexaria Bioscience has 7 employees. |
| Who is the CEO of Lexaria Bioscience? | Lexaria Bioscience's CEO is Mr. Richard C. Christopher. |
| Is Lexaria Bioscience publicy listed? | Yes, Lexaria Bioscience is a public company listed on NAS. |
| What is the stock symbol of Lexaria Bioscience? | Lexaria Bioscience trades under LEXX ticker. |
| When did Lexaria Bioscience go public? | Lexaria Bioscience went public in 2006. |
| Who are competitors of Lexaria Bioscience? | Similar companies to Lexaria Bioscience include e.g. LTR Pharma, Starpharma, Schott Pharma, Nanoform. |
| What is the current market cap of Lexaria Bioscience? | Lexaria Bioscience's current market cap is $19.8M |
| What is the current revenue of Lexaria Bioscience? | Lexaria Bioscience's last 12 months revenue is $0.5M. |
| What is the current revenue growth of Lexaria Bioscience? | Lexaria Bioscience revenue growth (NTM/LTM) is 117%. |
| What is the current EV/Revenue multiple of Lexaria Bioscience? | Current revenue multiple of Lexaria Bioscience is 29.4x. |
| Is Lexaria Bioscience profitable? | Yes, Lexaria Bioscience is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
